A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Study Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- have a ≥ 3 month history of experiencing Stress Urinary Incontinence
- be willing to use the pessary investigational device to control stress incontinence
Exclusion Criteria:
- pregnant, lactating or planning to become pregnant during the study
- within 3 months post partum
- intrauterine device (IUD) placement of less than 6 months
- a history of Toxic Shock Syndrome (TSS) or symptoms consistent with TSS
- experience difficulty inserting or wearing an intra-vaginal device, including a tampon
- vaginal surgery, perineal surgery, uterine surgery, or abortion (spontaneous or induced) within the past 3 months
- has any Screening laboratory value outside the laboratory reference range considered clinically significant by the Investigator
- for any reason, the Investigator decides that the subject should not participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: pessary device
pessary (disposable intra-vaginal device)
|
pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pad Weight Gain
Time Frame: from the 14-day baseline period to the last 7 days of 14-day device usage period
|
Change from baseline as measured as reduction (improvement) in pad weight gain.
Positive values are indicative of efficacious outcome.
|
from the 14-day baseline period to the last 7 days of 14-day device usage period
|
|
Change in Stress Urinary Incontinence Episodes
Time Frame: from the 14-day baseline period to the last 7 days of 14-day device usage period
|
Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes.
Positive values are indicative of efficacious outcome.
|
from the 14-day baseline period to the last 7 days of 14-day device usage period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life as Measured by Incontinence Impact Questionnaire (IIQ-7)
Time Frame: baseline and end-of-treatment
|
The IIQ-7 is based on 7 questions referring to areas which may have been influenced or changed by accidental urine loss and/or prolapse.
These questions are assigned a value of, 0 = 'Not at all,' 1= 'Slightly,' 2 = 'Moderately,' or 3 'Greatly.'
The IIQ-7 is scored by taking the average score of items and then multiplying the average by 33 1/3 to put scores on a scale from 0 to 100.
A lower score is considered less impact to quality of life and a higher score reflects more impact to quality of life.
In the same manner, a reduction in scores from baseline reflects improved quality of life.
|
baseline and end-of-treatment
|
|
Change in Pad Weight Gain
Time Frame: from the 14-day baseline period to the first 7 days of 14-day device usage period
|
Change from baseline as measured as reduction (improvement) in pad weight gain.
Positive values are indicative of efficacious outcome.
|
from the 14-day baseline period to the first 7 days of 14-day device usage period
|
|
Change in Stress Urinary Incontinence Episodes
Time Frame: from the 14-day baseline period to the first 7 days of 14-day device usage period
|
Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes.
Positive values are indicative of efficacious outcome.
|
from the 14-day baseline period to the first 7 days of 14-day device usage period
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Responders for Pad Weight Gain
Time Frame: from the 14-day baseline period to the last 7 days of 14-day device usage period
|
from the 14-day baseline period to the last 7 days of 14-day device usage period
|
|
Percentage of Responders for SUI Episodes
Time Frame: from the 14-day baseline period to the last 7 days of 14-day device usage period
|
from the 14-day baseline period to the last 7 days of 14-day device usage period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Randall Severance, MD, Radiant Research, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2012099
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.